Strides Pharma Science Ltd Valuation Shifts to Very Attractive Amid Sector Volatility

Valuation Metrics Signal Enhanced Price Attractiveness

Strides Pharma’s current price-to-earnings (P/E) ratio stands at 14.43, a figure that is markedly lower than many of its peers in the pharmaceutical space. For context, Ajanta Pharma trades at a P/E of 36.33, Gland Pharma at 34.40, and Pfizer at 30.58, all of which are classified as very expensive or expensive by market standards. This relatively modest P/E ratio for Strides suggests that the stock is undervalued compared to sector benchmarks, offering investors a more reasonable entry point.

Similarly, the price-to-book value (P/BV) ratio of 2.89 further underscores the stock’s attractive valuation. While not the lowest in the sector, this P/BV is significantly more conservative than the valuations of several competitors, many of which command premiums due to their market positioning or growth prospects. The enterprise value to EBITDA (EV/EBITDA) ratio of 10.59 also supports this narrative, indicating that the company’s earnings before interest, taxes, depreciation, and amortisation are being valued at a reasonable multiple.

Comparative Sector Analysis Highlights Relative Value

When compared to other pharmaceutical companies, Strides Pharma’s valuation stands out as particularly compelling. For instance, J B Chemicals & Pharmaceuticals is trading at a P/E of 44.28 and an EV/EBITDA of 28.96, while Astrazeneca Pharma’s P/E ratio is an elevated 105.59 with an EV/EBITDA of 75.23. These multiples reflect high growth expectations and premium valuations that may not be sustainable in the current market environment.

In contrast, Strides’ valuation metrics suggest a more conservative market assessment, which could appeal to value-oriented investors seeking exposure to the pharmaceutical sector without the inflated multiples. This is especially relevant given the company’s return on capital employed (ROCE) of 15.60% and return on equity (ROE) of 15.82%, both of which indicate efficient capital utilisation and profitability that justify the current valuation.

Stock Performance and Market Context

Despite the improved valuation, Strides Pharma’s stock price has experienced a modest decline recently, with a day change of -1.28% and a current price of ₹862.85, down from the previous close of ₹874.05. The stock remains below its 52-week high of ₹1,024.90 but comfortably above its 52-week low of ₹551.00, indicating a degree of price stability amid market fluctuations.

Examining returns relative to the broader market, Strides Pharma has outperformed the Sensex over multiple time horizons. The stock delivered a 34.10% return over the past year compared to the Sensex’s 10.44%, and an impressive 502.95% return over three years versus the Sensex’s 38.28%. Even over five and ten years, Strides has outpaced the benchmark, with returns of 114.88% and 96.66% respectively, compared to the Sensex’s 61.92% and 256.13%. This long-term outperformance highlights the company’s resilience and growth potential despite recent sector headwinds.

Mojo Score and Grade Revision Reflect Caution

MarketsMOJO’s latest assessment downgraded Strides Pharma’s Mojo Grade from Hold to Sell on 16 February 2026, with a Mojo Score of 48.0. This downgrade signals caution, likely reflecting concerns over near-term operational challenges or sector-wide pressures. The Market Cap Grade remains low at 3, indicating limited market capitalisation strength relative to peers.

However, the valuation grade has improved from attractive to very attractive, suggesting that while the stock may face headwinds, its current price offers a compelling entry point for investors willing to tolerate short-term volatility. The PEG ratio of zero, while unusual, may indicate a lack of consensus on growth expectations or a temporary anomaly in earnings forecasts.

Financial Health and Dividend Yield

Strides Pharma’s financial metrics further support its valuation appeal. The company’s EV to capital employed ratio of 2.19 and EV to sales ratio of 2.03 indicate efficient use of capital and reasonable sales valuation. The dividend yield, though modest at 0.46%, provides a small income component for investors, complementing the company’s growth and profitability metrics.

These fundamentals, combined with a solid ROCE and ROE, suggest that Strides Pharma is generating healthy returns on invested capital, which should underpin sustainable earnings growth over the medium term.

Investor Takeaway: Balancing Value and Risk

Strides Pharma Science Ltd presents a nuanced investment case. On one hand, its valuation metrics have improved significantly, with P/E and P/BV ratios now categorised as very attractive relative to peers. This shift offers a compelling opportunity for value investors seeking exposure to the Pharmaceuticals & Biotechnology sector at a discount to historical and peer averages.

On the other hand, the downgrade in Mojo Grade to Sell and a modest Mojo Score of 48.0 highlight underlying risks that investors must consider. These may include sector-specific challenges, regulatory pressures, or company-specific operational issues that could impact near-term performance.

Given the stock’s strong long-term returns relative to the Sensex and solid profitability metrics, investors with a higher risk tolerance may view the current valuation as a favourable entry point. However, cautious investors should weigh these positives against the broader market context and the company’s recent rating downgrade.

Ultimately, Strides Pharma’s improved valuation parameters signal a shift towards price attractiveness that could attract renewed investor interest, especially if operational performance stabilises and sector conditions improve.

Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today